Pfizer SG&A decreased by 28.9% to $2.96B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.3%, from $3.03B to $2.96B. Over 4 years (FY 2021 to FY 2025), SG&A shows relatively stable performance with a 2.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.92B | $2.90B | $4.10B | $2.59B | $3.05B | $3.39B | $4.65B | $3.42B | $3.50B | $3.28B | $4.58B | $3.50B | $3.72B | $3.24B | $4.27B | $3.03B | $3.42B | $3.19B | $4.16B | $2.96B |
| QoQ Change | — | -0.8% | +41.6% | -36.8% | +17.5% | +11.3% | +37.0% | -26.4% | +2.3% | -6.2% | +39.4% | -23.6% | +6.4% | -12.7% | +31.8% | -29.1% | +12.7% | -6.7% | +30.6% | -28.9% |
| YoY Change | — | — | — | — | +4.3% | +17.0% | +13.2% | +31.8% | +14.7% | -3.2% | -1.5% | +2.3% | +6.3% | -1.1% | -6.6% | -13.3% | -8.1% | -1.8% | -2.6% | -2.3% |
Range$2.59B – $4.65B
CAGR+0.3%
Avg YoY Growth+3.1%
Median YoY Growth-1.3%
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $2.47B | $2.25B | $3.07B | $2.19B | $2.31B | $2.21B | $2.90B | $2.13B |
| Total | $3.72B | $3.24B | $4.27B | $3.03B | $3.42B | $3.19B | $4.16B | $2.96B |
SG&A at Other Companies
Frequently Asked Questions
- What is Pfizer's sg&a?
- Pfizer (PFE) reported sg&a of $2.96B in Q1 2026.
- How has Pfizer's sg&a changed year-over-year?
- Pfizer's sg&a decreased by 2.3% year-over-year, from $3.03B to $2.96B.
- What is the long-term trend for Pfizer's sg&a?
- Over 4 years (2021 to 2025), Pfizer's sg&a has grown at a 2.1% compound annual growth rate (CAGR), from $12.70B to $13.79B.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.